Biotech company producing cultivated animal fat from pig and cow stem cells as a drop-in ingredient for plant-based meat and food manufacturing.
Green Score
- Greenwashing risk
- medium
- Data confidence
- low
- Method
- how it is calculated
Climate Impact & Solution35%52
Does the core business genuinely avoid or reduce emissions, or build climate resilience? Share of revenue that is actually 'green'. Fossil-dependent models score low.
The core business model credibly targets displacement of high-impact conventional animal agriculture and problematic plant oils (palm, coconut) used in plant-based meat, but the company is pre-commercial, operates only a pilot facility, and has published no independent LCA quantifying actual avoided emissions — bioreactor energy intensity at scale remains an unresolved open question that could significantly erode the climate benefit.
Decarbonization & Targets20%5
Credible, science-based targets (SBTi), a real net-zero plan with progress to date, and CDP disclosure — not just a dated press release.
No SBTi-validated targets, no CDP disclosure, no net-zero roadmap, and no independently verified emissions baseline were found in any public source; the company makes qualitative sustainability claims but has made no quantified, time-bound climate commitments whatsoever.
ESG & Operations15%38
Operational footprint, labour and social practices, and governance quality across the company's own operations and supply chain.
The company scores moderately on animal welfare (no live animal slaughter in its process) and avoids antibiotics and deforestation-linked inputs, but as an early-stage startup there is no disclosed governance structure, no published labour or supply-chain policy, no board diversity reporting, and operational ESG data is entirely absent from public sources.
Transparency & Verification15%18
Quality of disclosure, independent third-party verification, and how much hard data backs the company's claims.
Sustainability claims ('low carbon process', 'uses less habitable land') originate exclusively from founder statements and marketing copy; no LCA, no third-party audit, no sustainability report, no regulatory filing with environmental data, and no CDP or GRI disclosure was found — disclosure quality is minimal for a company actively marketing a climate benefit.
Integrity15%82
Controversies, litigation, pollution, fossil-fuel lobbying, conflict-zone involvement and governance scandals. Higher means cleaner.
No material controversies, litigation, regulatory sanctions, fossil-fuel lobbying, or governance scandals were identified; the company's founders and investors (Collaborative Fund, Fine Structure Ventures) are aligned with sustainability-oriented missions, and no conflict-of-interest issues surfaced.
Why it's on ClimateTicker
Hoxton Farms sits on a genuinely plausible mitigation pathway: replacing land-intensive conventional animal fat and deforestation-linked palm/coconut oils in plant-based meat with bioreactor-grown cultivated fat could meaningfully cut emissions and land use at scale. However, the company is pre-commercial, has published no life-cycle assessment, and all environmental benefit claims remain self-asserted by founders with no independent verification — the climate case is directionally sound but currently unproven.
Controversy & Greenwashing Watch
Founders publicly describe the process as 'low carbon' and environmentally superior to conventional animal agriculture, but no independent life-cycle assessment or third-party audit supports these claims; bioreactor energy intensity at commercial scale is a known unresolved variable in the cultivated food industry.insights.figlobal.com
Cultivated fat has not received novel food approval in the EU or UK, and no US FDA clearance has been announced, meaning the product cannot legally be sold commercially in its primary target markets, creating material uncertainty around the climate impact delivery timeline.foodnavigator.com
Community Reviews
No reviews yet. Be the first to share your experience!
ClimateTicker assessments are evidence-based research, not investment advice. Companies and readers can challenge a factual claim or submit better evidence.